SCHEMBL6136160

SCHEMBL6136160

CCN(C(=O)NCc1ccc(Cc2c(-c3ccc(O)cc3)ccc3cc(O)ccc23)cc1)c1ccc(O)cc1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 2/20 0.44
▸ ESR2 Q92731 2/20 0.44
▸ HDAC1 Q13547 2/20 0.41
▸ HDAC6 Q9UBN7 2/20 0.41
▸ PDK1 Q15118 11/20 0.34
▸ PTPN1 P18031 1/20 0.33
▸ ACP1 P24666 1/20 0.33
▸ LTB4R2 Q9NPC1 1/20 0.33
▸ POLA1 P09884 1/20 0.33
▸ PDK2 Q15119 2/20 0.33
▸ PDK3 Q15120 2/20 0.33
▸ PDK4 Q16654 2/20 0.33
▸ JAK2 O60674 1/20 0.32
▸ JAK1 P23458 1/20 0.32
▸ TYK2 P29597 1/20 0.32
▸ JAK3 P52333 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6136130 0.96 ESR1 (0.41) ESR1ESR2HDAC1HDAC6PDK1
SCHEMBL6136061 0.95 ESR1 (0.41) ESR1ESR2HDAC1HDAC6PDK1
SCHEMBL6136296 0.94 ESR1 (0.45) ESR1ESR2HDAC1HDAC6PDK1
SCHEMBL6136101 0.89 ESR1 (0.46) ESR1ESR2HDAC1HDAC6PDK1
SCHEMBL6136002 0.85 ESR1 (0.43) ESR1ESR2HDAC1PDK1PTPN1
SCHEMBL6136079 0.85 ESR1 (0.42) ESR1ESR2PDK1POLA1
SCHEMBL6136484 0.84 ESR1 (0.44) ESR1ESR2HDAC1HDAC6PTPN1
SCHEMBL6136211 0.84 ESR1 (0.38) ESR1ESR2HDAC1HDAC6POLA1
SCHEMBL6136242 0.83 ESR1 (0.47) ESR1ESR2PDK1PDK2PDK3
SCHEMBL6136378 0.79 MTOR (0.48) ESR1ESR2HDAC1HDAC6PDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0895989-B1 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity LILLY CO ELI (US) 2005-05-18 — — EP claimed
US-6509356-B1 Estrogen inhibitory activity method for the treatment of breast cancer in a woman comprising administering to a patient a therapeutically effective amount of a compound ELI LILLY AND COMPANY 2003-01-21 — — US claimed
WO-1999007377-A1 1-[4-(SUBSTITUTED ALKOXY)BENZYL]NAPHTHALENE COMPOUNDS HAVING ESTROGEN INHIBITORY ACTIVITY ELI LILLY AND COMPANY (US) 1999-02-18 — — WO claimed
EP-0895989-A1 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity ELI LILLY AND COMPANY (US) 1999-02-10 — — EP claimed
EP-0895989-B1 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity LILLY CO ELI (US) 2005-05-18 — — EP disclosed
US-6509356-B1 Estrogen inhibitory activity method for the treatment of breast cancer in a woman comprising administering to a patient a therapeutically effective amount of a compound ELI LILLY AND COMPANY 2003-01-21 — — US disclosed
WO-1999007377-A1 1-[4-(SUBSTITUTED ALKOXY)BENZYL]NAPHTHALENE COMPOUNDS HAVING ESTROGEN INHIBITORY ACTIVITY ELI LILLY AND COMPANY (US) 1999-02-18 — — WO disclosed
EP-0895989-A1 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity ELI LILLY AND COMPANY (US) 1999-02-10 — — EP disclosed
Send feedback